Your browser doesn't support javascript.
loading
Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine.
Wang, Mengqi; Lan, Duo; Dandu, Chaitu; Ding, Yuchuan; Ji, Xunming; Meng, Ran.
Afiliação
  • Wang M; Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
  • Lan D; Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100053, China.
  • Dandu C; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
  • Ding Y; Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
  • Ji X; Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, 100053, China.
  • Meng R; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
BMC Neurol ; 23(1): 44, 2023 Jan 27.
Article em En | MEDLINE | ID: mdl-36707824
ABSTRACT
BACKGROUND AND

PURPOSES:

There has been both great interest in and skepticism about the strategies for headache inhibition in patients with patent foramen ovale and migraines (PFO-migraine). Furthermore, many questions remain about the fundamental pathophysiology of PFO-migraines. Herein, the inhibiting effect of normobaric oxygenation (NBO) on PFO-migraine was analyzed.

METHODS:

This real-world self-control study consecutively enrolled patients during the ictal phase of migraines who had patent foramen ovale (PFO) confirmed by Trans esophageal Ultrasound(TEE). After comparing the baseline arterial oxygen partial pressure (PaO2) in their blood gas with that of healthy volunteers, all the patients with PFO-migraine underwent treatment with NBO (8 L/min. for 1 h/q8h) inhalation through a mask. Their clinical symptoms, blood gas, and electroencephalograph (EEG) prior to and post-NBO were compared.

RESULTS:

A total of 39 cases with PFO-migraine (in which 36% of participants only had a small-aperture of PFO) and 20 non-PFO volunteers entered the final analysis. Baseline blood gas analysis results showed that the PaO2 in patients with PFO-migraine were noticeably lower than PaO2 levels in non-PFO volunteers. After all patients with PFO-migraines underwent NBO treatment, 29(74.4%) of them demonstrated dramatic headache attenuation and a remarkable increase in their arterial PaO2 levels after one time treatment of NBO inhalation (p < 0.01). The arterial PaO2 levels in these patients gradually went down during the following 4 h after treatment. 5 patients finished their EEG scans prior to and post-NBO, and 4(80%) were found to have more abnormal slow waves in their baseline EEG maps. In the follow up EEG maps post-NBO treatment for these same 4 patients, the abnormal slow waves disappeared remarkably.

CONCLUSIONS:

Patients with PFO-migraine may derive benefit from NBO treatment. PFOs result in arterial hypoxemia due to mixing of venous blood, which ultimately results in brain hypoxia and migraines. This series of events may be the key pathologic link explaining how PFOs lead to migraines. NBO use may attenuate the headaches from migraines by correcting the hypoxemia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Forame Oval Patente / Transtornos de Enxaqueca Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Forame Oval Patente / Transtornos de Enxaqueca Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article